Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2771-2779

  Paoletti, Costanza ^a   Li, Yufeng ^b   Muñiz, Maria C ^a   Kidwell, Kelley M ^a,c   Aung, Kimberly ^a   Thomas, Dafydd G ^a   Brown, Martha E ^a   Abramson, Vandana G ^d   Irvin, William J ^e,f   Lin, Nancy U ^g   Liu, Minetta C ^h   Nanda, Rita ⁱ   Nangia, Julie R ^j   Storniolo, Anna M ^k   Traina, Tiffany A ^l   Vaklavas, Christos ^b   Van Poznak, Catherine H ^a   Wolff, Antonio C ^m   Forero Torres, Andres ^b   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Bon Secours Health System   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h GEORGETOWN UNIVERSITY HOSPITAL   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TIGATUZUMAB; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; CLINICAL TRIAL; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR EMBOLISM;

ADULT; AGED; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMARKERS, TUMOR; CELL COUNT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PACLITAXEL; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84940993817     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2781     Document Type: Article

References (16)

1. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
2. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9:3731-41.
3. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
4. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32: 3483-9.
5. Paoletti C, Smerage J, Hayes DF. Circulating tumor cells as a marker of prognosis. Princip Prac Oncol 2012;26:1-8.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
7. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101: 61-6.
8. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis. J Pathol 1999;187:567-72.
9. Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M, et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 2013;7:680-92.
10. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 2010;16: 5233-43.
11. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011;178:989-96.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
13. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32.
14. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, et al. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol 2009;219:287-93.
15. Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001;7:4080-5.
16. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;158:1110-22.